WO2009119890A1 - Dnaメチル化測定方法 - Google Patents
Dnaメチル化測定方法 Download PDFInfo
- Publication number
- WO2009119890A1 WO2009119890A1 PCT/JP2009/056782 JP2009056782W WO2009119890A1 WO 2009119890 A1 WO2009119890 A1 WO 2009119890A1 JP 2009056782 W JP2009056782 W JP 2009056782W WO 2009119890 A1 WO2009119890 A1 WO 2009119890A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dna
- stranded
- region
- base sequence
- primer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6858—Allele-specific amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
Definitions
- the present invention relates to a method for measuring the content of methylated DNA in a target DNA region in genomic DNA contained in a biological specimen.
- methylation in the target DNA region in the genomic DNA is performed.
- There are methods for measuring the content of DN A eg Nucleic Acids Res. 1994 Aug 11; 22 (15): 2990-7, and Proc Natl Acad Sci US A. 1 997 Mar 18; 94 (6): 2284 -See 9).
- this measurement method first, it is necessary to extract DNA containing the target DNA region from genomic DNA-derived DNA samples, and the extraction operation is complicated.
- a method for measuring the content of methylated DNA in the target region of the extracted DNA for example, (1) After modifying the DNA with sulfite, etc., DNA synthesis by DNA polymerase can be performed.
- a method for amplifying a target region by subjecting it to a polymerase chain reaction hereinafter, also referred to as PCR.
- PCR polymerase chain reaction
- a method for amplifying a target region by providing the information is known. In any of these methods, it takes time to modify DNA for detection of methylation and subsequent purification of the product, preparation of a reaction system for PCR, confirmation of DNA amplification, and the like. Disclosure of the invention
- An object of the present invention is to provide a method for easily measuring the content of methylated DNA in a target DNA region in genomic DNA contained in a biological specimen.
- the following inventions are provided. [Invention 1]
- a method for measuring the content of methylated DNA in a target DNA region in genomic DNA contained in a biological specimen A method for measuring the content of methylated DNA in a target DNA region in genomic DNA contained in a biological specimen
- the single-stranded DNA selected in the second step is used as a saddle, and the single-stranded DNA is double-stranded by extending the primer once using the single-stranded immobilized oligonucleotide as a primer.
- the process has a process (pre-process) for separating the stretched double-stranded DNA obtained in the third process into a single-stranded state.
- step A A DNA in a single-stranded state selected in the first step, using the single-stranded immobilized oligonucleotide as a primer, and extending the primer once to form a DNA in the single-stranded state Step A2 in which DNA is elongated as double-stranded DNA, step A (this step) having:
- the stretched double-stranded DNA obtained in each of the above steps can be separated into a single-stranded state and then turned back to detect methylated DNA in the target DNA region.
- the single-stranded DNA positive strand
- the target DNA region is not included.
- a step of adding a single-stranded oligonucleotide (negative strand) that is in a free state into the reaction system (additional previous step), and
- Step C 1 The DNA in the single-stranded state selected in Step C 1 is used as a saddle, the single-stranded oligonucleotide (negative strand) is used as a primer, and the primer is extended once, thereby Step C, which includes Step C 2 for extending DNA in a double-stranded state as double-stranded DNA (this step)
- An unfolded double-stranded DNA which is an undigested product obtained through the third step and the pre-addition step, is formed without an amethylated CpG pair at the recognition site of the methylation-sensitive restriction enzyme.
- Step C 1 The DNA in the single-stranded state selected in Step C 1 is used as a saddle, the single-stranded oligonucleotide (negative strand) is used as a primer, and the primer is extended once, thereby Step C, which has Step C2 to extend DNA in a double-stranded state as double-stranded DNA (this step)
- a method for measuring a methylation ratio which further comprises the following two processes.
- the fifth step of amplifying the DNA of the target DNA region (total amount of methylated DNA and unmethylated DNA) to a detectable amount and quantifying the amount of amplified DNA; as well as,
- Inventions 1 to 3 wherein the DNA sample derived from genomic DNA contained in a biological sample is a DNA sample previously digested with a restriction enzyme that does not use the target DNA region of the genomic DNA as a recognition cleavage site. 9. The method according to any one of 9.
- Digestion treatment with a methylation sensitive restriction enzyme for masking consisting of a single-stranded DNA (positive chain) containing the target DNA region and a base sequence complementary to the base sequence of the recognition site of the methylation sensitive restriction enzyme
- the first (A) step for producing a single-stranded DNA in which the recognition site of the methylation-sensitive restriction enzyme is protected by mixing with an oligonucleotide, and the one selected in the first (A) step The method according to any one of Inventions 1 to 11, which is a digestion treatment comprising the first step (B) of digesting a double-stranded DNA with a methylation-sensitive restriction enzyme.
- methylation-sensitive restriction enzyme is a restriction enzyme having a recognition cleavage site in a target DNA region of genomic DNA contained in a biological sample.
- a method for measuring the content of methylated DNA in a target DNA region of genomic DNA contained in a biological specimen A method for measuring the content of methylated DNA in a target DNA region of genomic DNA contained in a biological specimen
- the process has a process (pre-process) for once separating the stretched double-stranded DNA obtained in the third process into a single-stranded state.
- Step A 1 for selecting the DNA in the single-stranded state by base pairing the generated single-stranded DNA (positive strand) with the forward primer (negative strand).
- a DNA in the single-stranded state selected in Step A 1 is in a saddle shape, and the primer for the forward direction is used as an extension primer, and the primer is extended once, thereby being in the single-stranded state.
- a step A (this step) having a step A2 for extending the DNA as double-stranded DNA; and
- each step of the fourth step is repeated in the target DNA region by repeating the elongated double-stranded DNA obtained in each step and separating it into a single-stranded state.
- the single-stranded immobilized oligonucleotide is a single-stranded immobilized oligonucleotide in which the 5 or 3 ′ end is immobilized.
- the single-stranded DNA positive strand
- the target DNA region is not included.
- the method according to invention 15 or 16 wherein base pairing is carried out in a reaction system containing a divalent cation when base-pairing with a single-stranded immobilized oligonucleotide having a complementary base sequence.
- a method for measuring a methylation ratio which further comprises the following two steps as the steps of the method according to the invention 15 or 16.
- Invention 15 wherein the DNA sample derived from genomic DNA contained in a biological sample is a DNA sample that has been previously digested with a restriction enzyme that does not use the target DNA region of genomic DNA as a recognition cleavage site. Or the method according to 16.
- a digestion treatment with a methylation-sensitive restriction enzyme consists of a single-stranded DNA (positive strand) containing the target DNA region and a base sequence complementary to the base sequence of the recognition site of the methylation-sensitive restriction enzyme.
- the method according to the invention 15 or 16 which is a digestion treatment comprising the step (B) of digesting the strand DNA with a methylation sensitive restriction enzyme.
- methylation sensitive restriction enzyme is a restriction enzyme having a recognition cleavage site in a target DNA region of genomic DNA contained in a biological specimen.
- FIG 1 shows that, in the examples, the prepared samples are labeled “A (no treatment)” and “B (fo treatment)”.
- FIG. 6 is a diagram showing the results of electrophoresis of 2% agarose gel on the amplified product.
- the “biological specimen” in the present invention for example, a cell lysate, a tissue lysate (herein, tissue has a broad meaning including blood, lymph nodes, etc.) or in mammals, Biological samples such as body fluids such as plasma, serum and lymph, body secretions (urine, milk, etc.) and genomic DNA obtained by extraction from these biological samples can be mentioned.
- the biological specimen may contain, for example, a microorganism or a virus. Therefore, the “genomic DNA” in the present invention includes not only the genomic DNA of the biological specimen itself but also the genomic DNA of microorganisms and viruses contained in the biological specimen. Baby When the sample derived from a milk animal is blood, the use of the present invention in a periodic health examination or a simple test can be expected.
- DNA may be extracted using a commercially available DNA extraction kit.
- plasma or serum is prepared from blood according to a normal method, and the prepared plasma or serum is used as a specimen, and free DNA contained therein (derived from cancer cells such as stomach cancer cells) Analysis of cancer cells such as gastric cancer cells, avoiding blood cell-derived DNA, and detecting cancer cells such as gastric cancer cells and tissues containing them Sensitivity can be improved.
- the genomic DNA-derived DNA sample may be a DNA sample that has been purified in advance by a predetermined method. Normally, there are four types of bases that make up a gene (genomic DNA). Among these bases, it is known that only cytosine is methylated. Such DNA methylation modification is based on the nucleotide sequence shown by 5, -CG-3 '(C represents cytosine). , G represents guanine.Hereafter, the base sequence may be written as “CpG”.) It is limited to cytosine. The site that is methylated in cytosine is position 5.
- methylated DNA in the present invention means DNA produced by such methyli modification.
- the “CpG pair” in the present invention means a double-stranded oligonucleotide formed by base pairing of a base sequence represented by CpG and a complementary CpG.
- the “target DNA region” in the present invention (hereinafter sometimes referred to as a target region) is a DNA region to be examined for the presence or absence of methylation of cytosine contained in the region. And at least one recognition site for a methylation sensitive restriction enzyme. For example, Lysy 1 oxidase ⁇ HRAS-like suppressor N bA305P22. 2.
- the nucleotide sequence comprising two or more include the nucleotide sequence of genomic DNA containing exon 1 of the Lysyl oxidase gene derived from human and a promoter region located 5 ′ upstream thereof.
- nucleotide sequence represented by SEQ ID NO: 1 (corresponding to the nucleotide sequence represented by nucleotide numbers 16001 to 18661 of the nucleotide sequence described in Genbank Accession No. AF270645).
- the ATG codon that encodes the amino terminal methionine of Lysyl oxidase protein derived from human is represented by nucleotide numbers 2031 to 2033.
- the nucleotide sequence of the above exon 1 is represented by nucleotide number 1957-2661.
- the cytosine in G exhibits a high methylation frequency (ie, hypermethylation) in cancer cells such as gastric cancer cells.
- cytosine with high methylation frequency in gastric cancer cells for example, in the base sequence represented by SEQ ID NO: 1, base numbers 1539, 1560, 1574, 1600, 1623, 1635, 1644, 1654, 1661, Cite cytosine such as 1682, 1686, 16 96, 1717, 1767, 1774, 1783, 1785, 1787, 1795 etc. Can do.
- the useful protein gene is an HRAS-like suppressor gene, it is represented by C p G present in the base sequence of the promoter region, untranslated region or translated region (coding region).
- the base sequence of genomic DNA containing exon 1 of the HRAS-like suppressor gene derived from human and a promoter region located 5 'upstream thereof can be mentioned. More specifically, the base sequence represented by SEQ ID NO: 2 (corresponding to the base sequence represented by base numbers 172001 to 173953 of the base sequence described in Genbank Accession No. AC068162) can be mentioned. In the base sequence represented by SEQ ID NO: 2, the base sequence of exon 1 of the human-derived HRAS-like suppress or gene is represented by base numbers 1743-1953.
- cytosine having high methylation frequency in gastric cancer cells for example, in the base sequence represented by SEQ ID NO: 2, base numbers 1316, 1341, 1357, 1359, 1362, 1374, 1390, 1399, 1405, 1409, 1414, 1416, 1422, 1428, 1434, 1449, 1451, 1454, 1463, 1469, 1477, 1479, 1483, 1488, 1492, 1494, 1496, 1498, 1504, 1510, 1513, 1518, 1520
- the cytosine indicated by etc. can be mentioned.
- the useful protein gene is bA305P22.2.1 gene
- it is indicated by C p G present in the base sequence of the promoter region, untranslated region or translated region (coding region).
- the base sequence containing at least one base sequence is a genomic DNA base sequence containing exon 1 of human-derived bA305P22.2.1 gene and its 5, promoter region located upstream. More specifically, the base sequence represented by SEQ ID NO: 3 (corresponding to the base sequence represented by base numbers 13001 to 13889 of the base sequence described in Genbank Accession No. AL121673) can be mentioned. Sequence number In the nucleotide sequence shown in Fig.
- the ATG codon that encodes the methionine at the amino terminal of the human-derived bA305P22.2.1 protein is shown in nucleotide numbers 849 to 851, and the nucleotide sequence of exon 1 is It is shown in base numbers 663-889.
- the cytosine in G shows a high methylation frequency (ie, hypermethylation) in cancer cells such as gastric cancer cells.
- cytosine having a high methylation frequency in gastric cancer cells for example, in the base sequence represented by SEQ ID NO: 3, base numbers 329, 335, 337, 351, 363, 373, 405, 424, 427 , 446, 465, 472, 486, and the like.
- the useful protein gene is a Gamma filamin gene
- it is represented by C p G present in the base sequence of the promoter region, untranslated region or translated region (coding region).
- Examples of the base sequence including one or more base sequences include the base sequence of genomic DNA containing exon 1 of the Gamma filamin gene derived from human and a promoter region located 5 ′ upstream thereof.
- a base sequence represented by SEQ ID NO: 4 (corresponding to a complementary sequence of the base sequence represented by base numbers 63528 to 64390 of the base sequence described in Genbank Accession No. AC074373) can be mentioned.
- the ATG codon encoding the amino terminal methionine of the Gamma filamin protein derived from human is shown in base numbers 572 to 574.
- the base sequence of exon 1 is Base numbers 463 to 863.
- cytosine having a high methylation frequency in gastric cancer cells for example, in the base sequence represented by SEQ ID NO: 4, base numbers 329, 333, 337, 350, 353, 360, 363, 370, 379, 382, 384, 409, 414, 419, 426, 432, 434, 445, 449, 459, 472, 474, 486, 490, 503, 505
- the cytosine shown by etc. can be mention
- the useful protein gene is a HAND1 gene
- Examples of the base sequence containing one or more include the base sequence of genomic DNA containing exon 1 of the HAND1 gene derived from human and the promoter region located 5 ′ upstream thereof. More specifically, And a nucleotide sequence represented by SEQ ID NO: 5 (corresponding to a complementary sequence of the nucleotide sequence represented by nucleotide numbers 243 03 to 26500 of the nucleotide sequence described in Genbank Accession No. AC026688).
- the ATG codon encoding the amino acid at the amino terminal of the HAND1 protein derived from human is represented by nucleotide numbers 1656 to 1658, and the nucleotide sequence of exon 1 is Base numbers 1400 to 2198 are shown.
- the cytosine for example, shows a high methylation frequency (ie, hypermethylation) in cancer cells such as gastric cancer cells.
- cytosine having a high methyline frequency in gastric cancer cells for example, in the base sequence represented by SEQ ID NO: 5, the base numbers 1153, 1160, 1178, 1187, 1193, 1218, 1232, 1266, 1272, Examples include cytosine represented by 1292, 1305, 1307, 1.3 16, 1356, 1377, 1399, 1401, 1422, 1434, and the like. More specifically, for example, when the useful protein gene is the Homologue of RIKEN 2210016F16 gene, it is represented by CG present in the base sequence of the promoter region, untranslated region or translated region (coding region).
- the nucleotide sequence containing one or more nucleotide sequences should be the genomic DNA sequence that contains exon 1 of the human-derived Homologue of RIKEN 2210016F16 gene, its 5, promoter region located upstream. More specifically, the nucleotide sequence represented by SEQ ID NO: 6 (the nucleotide sequence represented by nucleotide numbers 157056 to 159000 of the nucleotide sequence described in Genbank Accession No. AL354733) It corresponds to the complementary base sequence of the column. ).
- nucleotide sequence represented by SEQ ID NO: 6 the nucleotide sequence of exon 1 of the human-derived Homologue of RIKEN 2210016F16 gene is represented by nucleotide numbers 1392 to 1945.
- the cytosine in G shows a high methylation frequency (ie, hypermethylation) in cancer cells such as gastric cancer cells.
- cytosine having a high methyline frequency in gastric cancer cells for example, in the base sequence represented by SEQ ID NO: 6, the base numbers 1172, 1175, 1180, 1183, 1189, 1204, 1209, 1267, 1271, Examples include 1278, 1281, 1313, 1319, 1332, 1334, 1338, 1346, 1352, 1358, 1366, 1378, 1392, 1402, 1433, 1436, 1438, and the like.
- the base sequence represented by C p G present in the base sequence of the promoter region, untranslated region or translated region (coding region) is Examples of the nucleotide sequence containing one or more include the nucleotide sequence of genomic DNA containing exon 1 of the FLJ32130 gene derived from human and its 5, promoter region located upstream. More specifically, And a nucleotide sequence represented by SEQ ID NO: 7 (corresponding to a complementary nucleotide sequence of the nucleotide sequence represented by nucleotide numbers 1 to 2379 of the nucleotide sequence described in Genbank Accession No. AC002310).
- the ATG codon encoding the methionine at the amino acid end of the FLJ32130 protein derived from human is represented by nucleotide numbers 2136 to 2138, and the nucleotide sequence considered to be exon 1 is Base numbers 2136 to 2379 are shown.
- Cytosine in pG shows a high methylation frequency (ie, hypermethylation) in cancer cells such as gastric cancer cells.
- cytosine having a high methylation frequency in gastric cancer cells for example, in the base sequence represented by SEQ ID NO: 7, base numbers 1714, 1716, 1749, 1753, 1762, 1795, 1814, 1894 , 1911, 19
- the cytosine shown by 15, 1925, 1940, 1955, 1968 etc. can be mentioned.
- the useful protein gene is a PPARG angiopoietin-related protein gene
- the C p present in the base sequence of the promoter region, untranslated region or translated region (coding region)
- the nucleotide sequence containing one or more nucleotide sequences indicated by G is the nucleotide sequence of genomic DNA containing human-derived PPARG angiopoietin-related protein gene etason 1 and the 5 'upstream promoter region. More specifically, the base sequence represented by SEQ ID NO: 8 can be mentioned.
- the ATG codon encoding the amino acid methionine at the amino terminal of the human-derived PPARG angiopoietin-related protein protein is represented by the base numbers 717 to 719.
- the base sequence of the 5 ′ side part is shown in base numbers 1957 to 2661.
- the cytosine in the middle shows a high methylation frequency (ie, hypermethylation state) in cancer cells such as gastric cancer cells.
- cytosine with high methylation frequency in gastric cancer cells for example, in the base sequence represented by SEQ ID NO: 8, 'base numbers 35, 43, 51, 54, 75, 85, 107, 127, 129 143, 184, 194, 223, 227, 236, 251, 258, and the like.
- the useful protein gene is a Thrombomodulin gene
- the nucleotide sequence represented by C p G present in the base sequence of the promoter region, untranslated region or translated region (coding region).
- a base sequence of genomic DNA containing exon 1 of a Thrombomodulin gene derived from human and a promoter region located 5 ′ upstream thereof can be mentioned.
- a base sequence represented by SEQ ID NO: 9 (corresponding to a base sequence represented by base numbers 1 to 6096 of the base sequence described in Genbank Accession No. AF495471).
- SEQ ID NO: 9 the amino terminus of human-derived Thrombomodulin protein
- the ATG codon that encodes the end methionine is shown in nucleotide numbers 2590 to 2592
- the base sequence of exon 1 is shown in nucleotide numbers 2048 to 6096.
- the cytosine in G exhibits a high methylation frequency (ie, hyperraethylation) in cancer cells such as gastric cancer cells.
- cytosine having high methylation frequency in gastric cancer cells for example, in the base sequence represented by SEQ ID NO: 9, the base numbers 1539, 1551, 1571, 1579, 1581, 1585, 1595, 1598, 1601 1621, 1632, 1638, 1645, 1648, 1665, 1667, 1680, 1698, 1710, 1724, 1726, 1756, and the like. More specifically, for example, when the useful protein gene is p53-responsive gene 2 gene, it is indicated by CG present in the base sequence of the promoter region, untranslated region or translated region (coding region).
- Examples of the base sequence containing one or more base sequences include the genomic DNA base sequence containing exon 1 of human-derived p53-responsive gene 2 gene and its 5, promoter region located upstream. More specifically, the nucleotide sequence represented by SEQ ID NO: 10 (corresponding to the complementary sequence of the nucleotide sequence represented by nucleotide numbers 113501 to 116000 of the nucleotide sequence described in Genbank Accession No. AC009471). Can be given. In the base sequence represented by SEQ ID NO: 10, the base sequence of exon 1 of the human-derived p53-responsive gene 2 gene is represented by base numbers 1558 to 1808.
- Cytosine in the base sequence represented by C p G present in the base sequence represented by SEQ ID NO: 10 is high in, for example, cancer cells such as knee cancer cells], methylation frequency (ie, high methyl Indicates hypermethylation). More specifically, as cytosine having a high methyl baboon frequency in popliteal cancer cells, for example, in the base sequence represented by SEQ ID NO: 10, base numbers 1282, 1284, 1301, 1308, 1315, 1319, 1349, 1351 1357, 1361, 1365, 1378, 1383 and the like.
- Fibrillin gene Is a base sequence containing one or more base sequences represented by C p G present in the base sequence of the promoter region, non-translation region or translation region (coding region) of the fibrillin gene derived from human.
- the base sequence of genomic DNA containing 1 and 5 and its upstream promoter region can be raised.
- the base sequence represented by SEQ ID NO: 11 (Genbank Accession No. AC113387) It corresponds to a complementary sequence of the base sequence indicated by base numbers 118801 to 121000 of the base sequence described.
- the base sequence of exon 1 of Fibrillin 2 gene derived from human is represented by base numbers 1091 to 1345.
- Cytosine in the base sequence represented by C p G present in the base sequence represented by SEQ ID NO: 11 is, for example, a high methylation frequency (ie, hypermethylati (hypermethylati) in cancer cells such as spleen cancer cells). on)). More specifically, cytosine having a high methylation frequency in the spleen cancer cells, for example, in the base sequence represented by SEQ ID NO: 11, the base numbers 679, 687, 690, 699, 746, 773, 777, 783 795, 799, 812, 823, 830, 834, 843, and the like.
- the useful protein gene is a Neurofilaments gene
- the base represented by C p G present in the base sequence of the promoter region, untranslated region or translated region (coding region).
- the nucleotide sequence including one or more sequences include the genomic DNA nucleotide sequence containing exon 1 of the neurofilaments gene derived from human and its five promoter region located upstream.
- the nucleotide sequence represented by SEQ ID NO: 12 (corresponding to the complementary sequence of the nucleotide sequence represented by nucleotide numbers 28001 to 30000 of the nucleotide sequence described in Genbank Accession No. AF106564) can be used. .
- nucleotide sequence of exon 1 of the human-derived Neurofilaments gene is represented by nucleotide numbers 614 to 1694.
- cytosine in the nucleotide sequence represented by C p G present in the nucleotide sequence represented by SEQ ID NO: 1 2 has a high methylation frequency (that is, ⁇ methylation state ( hypermethylation)).
- cytosine having a high methylation frequency in a spleen cancer cell includes, for example, a nucleotide sequence represented by SEQ ID NO: 12 428, 432, 443, 451, 471, 475, 482, 491, 499, 503, 506, 514, 519, 532, 541, 5 44, 546, 563, 566, 572, 580, etc. Can do.
- C p present in the base sequence of the promoter region, untranslated region or translated region (coding region) Contains one or more base sequences indicated by G 3 ⁇ 4 ⁇ ⁇ ⁇ ⁇ 1 J can include the base sequence of genomic DNA containing exon 1 of the disintegrin and metalloproteinase doma in 23 gene derived from baboon and a promoter region located 5 ′ upstream thereof.
- nucleotide sequence represented by SEQ ID NO: 13 (corresponding to the nucleotide sequence represented by nucleotide numbers 21001 to 23300 of the nucleotide sequence described in Genbank Accession No. AC009225).
- nucleotide sequence of exon 1 of the disintegrin and metalloproteinase domain 23 gene derived from baboon is shown in nucleotide numbers 1194 to 1630 in the base sequence IJ represented by SEQ ID NO: 13.
- cytosine in the base sequence represented by CpG present in the base sequence represented by SEQ ID NO: 13 has a high methylation frequency (ie, hypermethylation state in cancer cells such as spleen cancer cells).
- cytosine with high methylation frequency in knee cancer cells for example, in the base sequence represented by SEQ ID NO: 13, the base numbers 998, 1003, 1007, 1011, 1016, 1018, 1020, 1026, 1028, 1031, 1035, 1041, 1043, 1045, 1051, 1053, 1056, 1060, 1066, 1068, 1070, 1073, 1093, 1096, 1106, 11 12, 1120, 1124, 1126 etc. I can give you.
- the useful protein gene is a G protein-coupled receptor 7 gene
- C p G present in the base sequence of the promoter region, untranslated region or translated region (coding region).
- the base sequence containing one or more base sequences shown in is a base sequence of genomic DNA containing exon 1 of the human G protein-coupled receptor 7 gene and a promoter region located 5 'upstream thereof. More specifically, the nucleotide sequence represented by SEQ ID NO: 14 (the nucleotide sequence represented by nucleotide numbers 75001 to 78000 of the nucleotide sequence described in Genbank Accession No. AC009800) Equivalent to. ). In the base sequence represented by SEQ ID NO: 14, the base sequence of exon 1 of the G protein-coupled receptor 7 gene derived from human is represented by base numbers 1666 to 2652.
- Cytosine in the base sequence represented by C p G present in the base sequence represented by SEQ ID NO: 14 is, for example, a high methylation frequency (ie, hypermethylated state) in cancer cells such as presumptive cancer cells. (Hypermethylation)). More specifically, cytosine having a high methylation frequency in spleen cancer cells includes, for example, the base sequence represented by SEQ ID NO: 14 in the base numbers 1480, 1482, 1485, 1496, 1513, 1526, 1542, 1560 1564, 1568, 1570, 1580, 1590, 1603, 1613, 1620 and the like.
- a useful protein gene is a G-protein coupled somatostatin and angiotensin—like peptide receptor interferon 3 ⁇ 4 :, a promoter region, a promoter region, an untranslated region or a translated region ( As a base sequence including one or more base sequences represented by CG existing in the base sequence of the coding region), human G-protein coupled somatostatin and angiotensin-like peptide receptor gene exon 1 and its 5, the nucleotide sequence of genomic DNA containing an upstream promoter region can be mentioned. More specifically, the nucleotide sequence represented by SEQ ID NO: 15 (described in Genbank Accession No.
- ⁇ cytosine with high methylation frequency in cancer cells for example, in the base sequence represented by SEQ ID NO: 15 in the base number 470, 472, 490, 497, 504, 506, 509, 514,
- the cytosine shown by 522, 540, 543, 552, 566, 582, 597, 610, 612 etc. can be mentioned.
- a useful protein gene is Solute carrier family 6 neurotranslator transporter noradrenalin member 2
- a base sequence containing one or more base sequences represented by C p G present in the base sequence of the promoter region, untranslated region or translated region (coding region) is a human-derived base sequence.
- Solute carrier family 6 neurotransmitter transporter noradrenalin member 2 Regression 1 The base sequence of genomic DNA containing 5 children, exon 1 and its 5 upstream promoter region. And a nucleotide sequence represented by SEQ ID NO: 16 (corresponding to a complementary sequence of the nucleotide sequence represented by nucleotide numbers 78801 to 81000 of the nucleotide sequence described in Genbank Accession No. AC026802). Base ⁇ shown in SEQ ID NO: 16 1 In J, the nucleotide sequence of exon 1 of the human-derived Solute carrier family 6 neurotransmitter transporter noradrenalin member 2 gene is represented by nucleotide numbers 1479 to 1804.
- Cytosine in the nucleotide sequence represented by C p G present in the nucleotide sequence represented by SEQ ID NO: 16 is highly methylated (ie, hypermethylated in a cancer cell such as a premature cancer cell). )) More specifically, as cytosine having a high methylation frequency in spleen cancer cells, for example, in the base sequence represented by SEQ ID NO: 16, the base numbers 1002, 1010, 1019, 1021, 1051, 1056, 1061, Examples include cytosine represented by 1063, 1080, 1099, 1110, 1139, 1141, 1164, 1169, 1184, and the like.
- “(amplified methylated DNA in the target DNA region to a detectable amount) and the amount of amplified DNA” refers to the genome contained in the biological specimen. This means the amount of methylated DNA in the target region in DNA after amplification itself, that is, the amount determined in the fourth step of the present invention. For example, when the biological specimen is 1 mL of serum, it means the amount of DNA amplified based on the methylated DNA contained in 1 mL of serum.
- the “methylation ratio” means the genomic DNA contained in a biological specimen.
- a DNA sample derived from genomic DNA contained in a biological sample is digested with a methylation-sensitive restriction enzyme.
- “Methylation-sensitive restriction enzyme” means, for example, a restriction enzyme that does not digest a recognition sequence containing methylated cytosine but can only digest a recognition sequence containing cytosine that is not methylated. . That is, in the case of DNA in which cytosine contained in a recognition sequence that can be originally recognized by a methylation-sensitive restriction enzyme is methylated, even if the methylation-sensitive restriction enzyme is allowed to act on the DNA, the D NA is not cut. On the other hand, in the case where the cytosine contained in the recognition sequence that can be originally recognized by the methylation-sensitive restriction enzyme is not methylated, the methylation-sensitive restriction enzyme can be allowed to act on the DNA.
- the DNA is cleaved.
- a methylation sensitive enzyme include HpaII, BstUI, Narl, SacII, Hhal and the like.
- the methylation sensitive restriction enzyme has already been clarified by Gruenbaum et al. (Nucleic Acid Research, 9, 2509-2515).
- a primer pair capable of amplifying the DNA containing the cytosine to be analyzed as a recognition sequence is used.
- performing PCR to examine the presence or absence of DNA amplification (amplified product).
- an amplification product is obtained.
- the ratio of cytosine to be analyzed can be measured. That is, if the genomic DNA contained in the biological specimen is methylated, the methylation sensitive restriction enzyme is contained in the biological specimen by utilizing the property that it does not cleave the methylated DNA. Susceptibility to methylation in genomic DNA It is possible to distinguish whether cytosine in the CpG pair existing in the restriction enzyme recognition site was methylated or not.
- the restriction on the genomic DNA contained in the biological sample is performed. If cytosine in at least one CpG pair present in the enzyme recognition site is not methylated, PCR amplification products will not be obtained, but they will be contained in biological samples. If cytosine in all C p G pairs existing in the recognition site of the methylation-sensitive restriction enzyme in genomic DNA has been methylated, PCR amplification products can be obtained.
- the genomic DNA contained in the biological specimen is genomic DNA derived from a mammal
- the first step may be performed as follows. Optimal 10X buffer (330mM Tris-Acetate pH 7.9, 660mM K0Ac, lOOmM for mammalian genomic DNA
- a digestion treatment with a methylation-sensitive restriction enzyme consists of a single-stranded DNA (positive strand) containing the target DNA region and a base sequence complementary to the base sequence of the recognition site of the methylation-sensitive restriction enzyme.
- the methylation sensitivity by mixing with nucleotides. Digestion of the single-stranded DNA selected in the first (A) step and the first (A) step with a methyl enzyme-sensitive restriction enzyme to produce a single-stranded DNA in which the recognition site of the sex restriction enzyme is protected It may be a digestion process comprising the first step (B).
- the “masking oligonucleotide” is an oligonucleotide consisting of a base sequence complementary to the base sequence of the recognition site of the methylation-sensitive restriction enzyme and contained in the target DNA region in single-stranded DNA. Complementary base pairing with at least one (or all) of the recognition sequences of methylation-sensitive restriction enzymes in several locations forms a duplex (ie, the two locations are duplicated). In a single-stranded state, the methylation-sensitive restriction enzyme based only on double-stranded DNA can be digested with the above site, and when the sample is single-stranded DNA, single-stranded DNA is used.
- Digestible methyl babies sensitive restriction enzyme Metal methyl babies sensitive restriction enzyme capable of digesting single-stranded DNA can also digest double-stranded DNA, and its digestion efficiency is higher for double-stranded DNA than for single-stranded DNA
- Oligonucleotide for improving the digestion efficiency of the site, and a double strand of a single-stranded DNA containing the target region of DN A and a single-stranded immobilized oligonucleotide An oligonucleotide that does not inhibit strand formation.
- the masking oligonucleotide is an oligonucleotide that cannot be used for the reaction of extending the extension primer using the reverse primer (positive strand) described later as an extension primer and the masking oligonucleotide (negative strand) as a saddle type.
- the base length is preferably 8 to 200 bases.
- One or more masking oligonucleotides may be mixed with genomic DNA-derived DNA trials. When multiple types are used, many of the recognition sites for the methylation-sensitive restriction enzyme of single-stranded DNA containing the target DNA region become double-stranded, and the methylation-sensitive restriction enzyme DNA described later Can be minimized.
- the masking oligonucleotide is digested if it is not methylated but not methylated among the recognition sequences of methylation-sensitive restriction enzymes in several locations contained in the target DNA region. It is particularly useful to design and use according to the desired location (for example, 100% methylated in patients with disease and 100% methylated in healthy subjects).
- DNA fragmentation As a concern in the digestion treatment with a methylation-sensitive restriction enzyme in the first step, there is a possibility that a recognition sequence containing cytosine that has not been methylated cannot be completely digested (so-called “DNA fragmentation”). . When such a concern becomes a problem, if there are many recognition sites for the methylation-sensitive restriction enzyme, “DNA fragmentation” can be minimized. It has one or more recognition sites for methylation-sensitive restriction enzymes, and the more recognition sites, the better. In the present invention or the method for measuring a methylation ratio described later, “a DNA sample derived from genomic DNA contained in a biological specimen” force. One preferred embodiment is that it is a treated DNA sample.
- digestion treatment is performed by directly using a restriction enzyme that does not use the target DNA region as a recognition cleavage site for genomic DNA-derived DNA samples contained in biological samples. May be implemented.
- a general restriction enzyme treatment method may be used as a digestion method with a restriction enzyme that does not use the target DNA region as a recognition cleavage site.
- This method is useful for eliminating the “DNA residue” as described above.
- a method for digesting a sample derived from genomic DNA contained in a biological sample with a methylation-sensitive restriction enzyme the same method as described above may be used when the biological sample is genomic DNA itself.
- methylation sensitivity of a large excess of methylation sensitive restriction enzyme for example, 500 times (10U) or more of 25 ng of DNA Perform digestion with sensitive restriction enzymes Just do it.
- Genomic DNA basically exists as double-stranded DNA.
- methylation-sensitive restriction enzymes that can digest single strands (eg, Hhal), but also methylation-sensitive restriction enzymes that can digest double-stranded DNA (eg, Hpall, BstUI, Narl). s SacII, Hhal, etc.) can be used.
- a single-stranded DNA (positive strand) containing the target DNA region is obtained from the digested DNA sample obtained in the first step, and the single-stranded DNA (positive strand) is obtained.
- Single-stranded immobilized oligonucleotide is a part of the 3 ′ end of single-stranded DN A (positive strand) containing the target DN A region (not including the target DN A region). ) Is a single-stranded immobilized oligonucleotide having a base sequence that is complementary to the above (hereinafter also referred to as the present immobilized oligonucleotide).
- This immobilized oligonucleotide is used to select single-stranded DNA (positive strand) containing the target DNA region from a DNA DNA-derived DNA sample contained in a biological specimen.
- This fixed oligonucleotide is preferably 5 to 50 bases in length.
- the 5 ′ terminal side of this immobilized oligonucleotide can be immobilized with the carrier, while the 3 ′ terminal side thereof is changed from the 5 ′ terminal to the 3 ′ terminal by the third step and step A 2 described later. It may be in a free state so as to allow a single extension reaction that proceeds once.
- the present immobilized oligonucleotide may be immobilized with a carrier at the 5 ′ or 3 ′ end. “What can be immobilized on a carrier” means a single-stranded DN containing the target DNA region.
- the immobilized oligonucleotide is immobilized on a carrier when A (positive strand) is selected.
- A positive strand
- the immobilized oligonucleotide even if it is immobilized by binding of the present immobilized oligonucleotide and carrier
- an oligonucleotide having a base sequence (hereinafter sometimes referred to as the present oligonucleotide) may be immobilized on a carrier according to a normal genetic engineering operation method or a commercially available kit / device. (Binding to solid phase).
- the resulting biotinylated oligonucleotide is coated with streptavidin (eg, a streptavidin-coated PCR tube, streptavidin-coated).
- streptavidin eg, a streptavidin-coated PCR tube, streptavidin-coated.
- magnetic beads For example, magnetic beads
- a molecule having an active functional group such as an amino group, an aldehyde group, or a thiol group was covalently bonded to the 5, terminal side of the oligonucleotide, and then the surface was activated with a silane cutting agent or the like.
- a method of covalently bonding to a support made of glass, silica or heat-resistant plastic through a spacer such as five triglycerides connected in series, a cross-linker or the like is also included.
- the immobilized oligonucleotide is a piotinylated oligonucleotide
- a DNA sample derived from a genomic DNA contained in a biological specimen is subjected to base pairing between a buffering buffer and biotinylated oligonucleotide (the single-stranded DNA (positive strand) and this immobilized oligonucleotide). Thereafter, the mixture is obtained by adding the present immobilized oligonucleotide and the carrier, so that the mixture is freed at this stage). The resulting mixture is then double-stranded DNA containing the target DNA region present in the genomic DNA-derived DNA sample contained in the biological specimen.
- the base pairing between the single-stranded DNA (positive strand) containing the target DNA region and the piotinylated oligonucleotide is referred to as biotinylated oligonucleotide.
- This is performed prior to fixation with the streptavidin-coated support, but this order does not matter. That is, for example, by adding a DNA sample derived from a genomic DNA contained in a biological specimen to a pyotinylated oligonucleotide immobilized on a support coated with streptavidin, a mixture is obtained.
- This operation is important in order to remove unfixed DNA or DNA floating in a solution digested with the restriction enzymes described below from the reaction solution. If these operations are insufficient, the DNA suspended in the reaction solution will be in the shape of a bowl, and an unexpected amplification product will be obtained in the amplification reaction. In order to avoid non-specific binding between the support and DNA in biological samples, a large amount of DNA having a completely different base sequence from the target region (eg, rat DNA in the case of human biological samples) To the biological specimen and perform the above operation.
- the target region eg, rat DNA in the case of human biological samples
- a single-stranded DN A (positive strand) containing the target DN A region and a part of the 3 ′ end of the single-stranded DN A (provided that the target DN A
- the base pairing is performed with a single-stranded immobilized oligonucleotide having a base sequence that is complementary to the base sequence in a reaction system containing a divalent cation.
- the divalent cation is a magnesium ion.
- the “reaction system containing a divalent cation” refers to an annealing buffer used for base pairing the single-stranded DNA (positive strand) and the single-stranded immobilized oligonucleotide. It means the reaction system such as those containing a divalent cation, specifically, for example, magnesite Information & Technology-ion components and salts (e.g., M g OA c 2, MgC l 2 , etc.) 1 mM ⁇ 60 OmM It is better to be included at a concentration of In the third step, the single-stranded DNA selected in the second step is used as a saddle shape, the single-stranded immobilized oligonucleotide is used as a primer, and the primer is extended once, whereby the single-stranded DNA is doubled.
- magnesite Information & Technology-ion components and salts e.g., M g OA c 2, MgC l 2 , etc.
- an extension reaction may be performed using DNA polymerase.
- the third step may be performed as follows.
- the single-stranded DNA containing the target DNA region selected in the second step is sterilized with ultrapure water (17.85 / L), optimal 10 X buffer (lOOmM Tris-HC1 pH 8.3, 500 mM) KC1, 15 mM MgCl 2 ) 3 ⁇ l 2 mM dNTP 3 ⁇ re 5 Betaine is added, then AmpliTaq (1 type of DNA polymerase 5 U / i L) is added to the mixture in a volume of 0.15 ⁇ L. Incubate for 2 hours at 37 ° C. Thereafter, the incubated solution is removed by pipetting or decantation, and then the TE buffer is added in an amount approximately equal to the volume of the biological specimen, and the TE buffer is removed by pipetting or decanting.
- optimal 10 X buffer (lOOmM Tris-HC1 pH 8.3, 500 mM) KC1, 15 mM MgCl 2 ) 3 ⁇ l 2 mM dNTP 3 ⁇ re
- TE buffer that is approximately equal to the volume of the biological sample.
- the TE puffer can be removed by pipetting or decanting.
- magnetic beads coated with streptavidin after fixing the beads with a magnet, first remove the solution by pipetting or decantation, and then add TE buffer equivalent to the volume of the biological specimen. Add and then remove the TE buffer by pipetting or decanting. Subsequently, the remaining solution is removed and washed (DNA purification) by performing such an operation several times.
- the third step has a step of separating the single-stranded DNA selected in the second step from the immobilized oligonucleotide and temporarily separating it into a single-stranded state, and is a single-stranded state generated.
- a step of separating the single-stranded DNA selected in the second step from the immobilized oligonucleotide and temporarily separating it into a single-stranded state, and is a single-stranded state generated.
- DNA (positive strand) as a mirror type
- the optimum 10 X buffer (lOOmM Tris-HCl pH 8.3, 500mM KC1, 15mM MgC12) to a 3 mu Les 2 mM dNTPs and 3 ⁇ Les 5 ⁇ betaine Chikara ⁇ E, then to the mixture
- AmpliTaq (1 type of DNA polymerase: 5 U / ⁇ L) to the surface, add sterile ultrapure water to make the volume 30 ⁇ , and incubate at 37 ° C for 2 hours.
- the third step may be performed independently of the fourth step, or may be performed continuously with the PCR reaction performed in the fourth step.
- the stretched double-stranded DNA obtained in the third step (not including the methylated C pG pair at the recognition site of the methylation sensitive restriction enzyme)
- a process of separating the elongated double-stranded DNA) into a single-stranded state (previous process), and as this process
- the single-stranded DNA is selected by base pairing the generated single-stranded DNA (positive strand) and the single-stranded immobilized oligonucleotide (negative strand).
- a step A (this step) having a step A 2 to extend and form the single-stranded DN A as a double-stranded DN A, and
- an extended double-stranded DNA that is an undigested product obtained in the third step (the methylation at the recognition site of the methylation-sensitive restriction enzyme) is performed.
- the stretched double-stranded DNA that does not contain the CpG pair in the state is once separated into a single-stranded state.
- an unfolded double-stranded DNA that is an undigested product obtained in the third step an extension that does not contain the CpG pair in the methylation sensitive restriction enzyme recognition site.
- Add the aeration buffer to the double-stranded DNA to obtain a mixture.
- the resulting mixture is then heated at 95 ° C. for several minutes.
- the single-stranded immobilized oligonucleotide (negative strand) Tm value is about 10 to 20 ° C lower! /, Cool quickly to temperature, and keep at that temperature for several minutes.
- the DNA in the single-stranded state selected in (i) above is used as a saddle type, the single-stranded immobilized oligonucleotide is used as a primer, and the primer is extended once, thereby the single-stranded state
- This DNA is elongated to form double-stranded DNA (ie, step A2 in step A).
- it may be carried out in accordance with the following description or the operation method in the extension reaction in the second step of the present invention described above.
- each step of the fourth step is repeated after separating the elongated double-stranded DNA obtained in each step into a single-stranded state (for example, step A).
- step B the methylated DNA in the target DNA region is amplified to a detectable amount, and the amount of amplified DNA is quantified.
- a target DNA region ie, a target region
- PCR a method for amplifying a target DNA region after digestion with a methylation sensitive restriction enzyme.
- an immobilized oligonucleotide can be used as a primer on one side, so that only the other primer is added and PCR is performed to obtain an amplification product. It will be fixed. In this case, if a primer previously labeled with fluorescence or the like is used and the label is used as an index, the presence or absence of an amplification product can be evaluated without performing a cumbersome operation such as electrophoresis.
- the PCR reaction solution for example, the DNA obtained in the third step of the present invention was added with 0.15 1 of a 50 ⁇ primer solution, 2.5 mM of 2 NTP dNTPs, 10 ⁇ buffer solution (lOOmM Tris-HC1 pH 8.3).
- the reaction may be carried out by adding an appropriate amount of betaine, DMSO, etc. at times.
- the above reaction solution is kept at 95 ° C. for 10 minutes, then at 95 ° C. for 30 seconds, then at 55 to 65 ° C. for 30 seconds, and further at 72 ° C. for 30 seconds.
- One condition is that the temperature is maintained for 30 to 40 cycles.
- the resulting amplified product is detected. For example, if a pre-labeled primer is used, the same washing and purification procedure as before is used. After implementation, the amount of fluorescent label immobilized can be measured.
- PCR when PCR is performed using a normal unlabeled primer, detection is performed by annealing the colloidal gold particles, probes labeled with fluorescence, etc., and measuring the amount of the probe bound to the target region. can do.
- real-time PCR may be used to obtain the amount of amplification product with higher accuracy.
- Real-time PCR is a method of monitoring PCR in real time and analyzing the obtained motor results by force kinetics. For example, high-precision quantification that can detect even a slight difference of about twice the gene amount. This method is known as the PCR method.
- Examples of the real-time PCR method include a method using a probe such as a saddle type-dependent nucleic acid polymerase probe, and a method using an intercalator such as Cyber Green. Commercially available equipment and kits for real-time PCR may be used.
- the detection is not particularly limited, and can be detected by any known method. In these methods, operations up to detection can be performed without changing the reaction vessel.
- a biotinylated oligonucleotide having the same base sequence as the immobilized oligonucleotide is used as a primer on one side, or a new biotinylated oligonucleotide is designed on the 3 'end side from the immobilized oligonucleotide and used as a primer on one side.
- the complementary region can be used to amplify the target region.
- the amplification product obtained is fixed if there is a support coated with streptavidin. For example, when PCR is performed in a streptavidin-coated PCR tube, it is fixed in the tube. Therefore, as described above, amplification products can be easily detected by using labeled primers.
- the solution containing the amplification product obtained by PCR is transferred to a container where the streptavidin-coated support is present, and the amplification product is immobilized.
- the detection may be performed as described above.
- the complementary primer that amplifies the target region must be a primer that can amplify a target region that has one or more methylation-sensitive restriction enzyme recognition sites and does not include that recognition site. The reason for this is as follows.
- the target region may be amplified by PCR after annealing with the base.
- a part of the 3 ′ end of the single-stranded DNA (positive strand) containing the target DNA region (provided that the target DN A It does not include the region.) It additionally has a step of adding a single-stranded oligonucleotide (negative strand) having a base sequence complementary to) to the reaction system (pre-addition step). Including such variants.
- Each of the fourth steps of the present invention further includes the following one step.
- step C1 Base pairing the generated single-stranded DNA (positive strand) with the single-stranded oligonucleotide (negative strand) added to the reaction system in the previous step above. And step C1 for selecting the DNA in the single-stranded state,
- Step C 1 The single-stranded DNA selected in Step C 1 is used as a saddle, the single-stranded oligonucleotide (negative strand) is used as a primer, and the primer is extended once.
- Step C 2 which includes the step C 2 for extending the single-stranded DNA as a double-stranded DNA to the C 2 step (this step)
- a step of adding a single-stranded oligonucleotide (negative strand) that is in a free state into the reaction system pre-addition step
- the resulting undigested double-stranded DNA that is formed by extension double-stranded DNA that is formed by extension that does not contain the CpG pair in the methylated state at the recognition site of the methylation-sensitive restriction enzyme.
- the method further comprises the following one step (hereinafter sometimes referred to as the present methylation ratio measuring method).
- Step C 1 The DNA in the single-stranded state selected in Step C 1 is used as a saddle, the single-stranded oligonucleotide (negative strand) is used as a primer, and the primer is extended once, thereby Step C, which has Step C2 to extend DNA in a double-stranded state as double-stranded DNA (this step)
- Step C which has Step C2 to extend DNA in a double-stranded state as double-stranded DNA
- a single-stranded DN containing the above-mentioned target DNA region is used.
- the single-stranded oligonucleotide (negative strand) added to the reaction system in the pre-addition step is a part of the 3 ′ end of single-stranded DNA (depleted, Does not include the intended DNA area.
- a 5 ′ end is a single-stranded oligonucleotide in a free state having the same base sequence as that of the single-stranded immobilized oligonucleotide
- the base sequence may be the same as the single-stranded immobilized oligonucleotide, or may be a short base sequence, or a long sequence.
- the reverse primer positive strand
- the single-stranded oligonucleotide negative strand
- an extension primer is used.
- the immobilized oligonucleotide is used as a primer on one side and PCR is performed by adding only the other primer when increasing the target region.
- PCR is performed by adding only the other primer when increasing the target region.
- other methods for example, for detecting the target product.
- PCR may be performed by adding a pair of primers. After performing such PCR, determine the amount of amplified product obtained.
- the fourth step has repeated steps.
- the “generated single-stranded DNA (positive strand)” in the first step A 1 means the operation of the first step 4 and the second and subsequent steps. In both operations of the fourth step, this means “generated“ free ”single-stranded DNA (positive strand)”.
- the generated single-stranded DNA (negative strand) j is defined as both in the first step of the fourth step and in the second and subsequent steps of the fourth step.” This means the “fixed” single-stranded DNA (positive strand) j that is generated, but if the fourth step additionally has a C step, the first step of the fourth step is performed.
- Step A Means “generated“ fixed ”single-stranded state (DNA) (positive strand)”, while in the second and subsequent rounds of the fourth step, “generated“ fixed ”single-stranded "DNA (positive strand)” in the state and “NA (positive strand) in the generated 'free” single strand state "
- the “stretched double-stranded DNA” obtained in each step of the fourth step is the same as that in the operation of the first and fourth steps.
- ⁇ In the recognition site of the methine leihi sensitive restriction enzyme, it means a double-stranded DNAJ formed by extension that does not contain an ammethyl CpG pair.
- step B in both the first step of the fourth step and the second and subsequent steps of the fourth step, all of the recognition sites for the methyli-sensitive restriction enzyme are in an amethyl state. It means “extended double-stranded DNA that is a C p G pair”.
- the fourth step further includes a C step.
- the “generated single-stranded DNA (positive strand)” in the C1 step is the same as the first step of the fourth step. In both the operation and the repetitive operations of the fourth step after the second round, this means “the generated“ free ”single-stranded state of DNA (positive chain)”.
- the present efforts include a methylation ratio measuring method (that is, the methylation ratio measuring method of the present invention) characterized in that it further includes the following two steps as the steps of the present invention.
- the present invention (including the modified method) is performed without performing the third step of the present invention (including the modified method). 4), the DNA of the target DNA region (the total amount of methylated DNA and unmethylated DNA) is amplified to a detectable amount, The fifth step of quantifying the amount of amplified DNA;
- the amount of DNA quantified by the fourth step of the present invention (including the modified method), and The sixth step of calculating the ratio of methylated DNA in the target DNA region based on the difference obtained by comparing with the amount of DNA quantified in the step
- the methylation ratio measuring method is as follows: It can be used in situations like this.
- abnormal DNA methylation occurs in various diseases (for example, cancer), and it is considered possible to measure the degree of various diseases by detecting this abnormal DNA methylation.
- there is a DNA region that is 100% methylated in genomic DNA contained in a biological specimen derived from a disease and if the DNA region is subjected to the present invention or the methylation ratio measurement method of the present invention, the DNA region is measured.
- the amount of methylated DNA increases.
- the DNA region that has a low methylation ratio in genomic DNA contained in a biological specimen of a healthy subject and a high methyloi sputum percentage in genomic DNA contained in a biological specimen of a diseased patient.
- the amount of methylated DNA is close to 0 in the case of a healthy person, while in the case of a patient with a disease. Since the value is significantly higher than that in healthy subjects, the “degree of disease” can be determined based on the difference in this value.
- the “degree of disease” here is the same as the meaning generally used in the field, and specifically, for example, when the biological specimen is a cell, it means the malignancy of the cell. For example, when the biological specimen is a tissue, it means the abundance of diseased cells in the tissue. Furthermore, when the biological specimen is plasma / serum, it means the probability that the individual has a disease. Therefore, the present invention or the present methylation ratio measuring method makes it possible to diagnose various diseases by examining methylation abnormality. Restrictions that can be used in various methods for measuring the amount of methylated DNA in the target region and measuring the methylation ratio in the present invention or the methyli cocoon ratio measurement method of the present invention Enzymes, primers or probes are useful as reagents in detection kits.
- the present invention also provides a detection kit containing these restriction enzymes, primers or probes as reagents, and a detection chip in which these primers or probes are immobilized on a carrier.
- methylation ratio measuring method includes use in the form of a detection chip or a detection chip as described above using the substantial principle of the method.
- L TE buffer solution was prepared.
- Group A (untreated group): 10 X buffer solution (330raM Tris-Acetate pH 7.9, 660 mM K0Ac, lOOmM MgOAc 2 , 5 mM Dithiothreitol) 5 IL and 10 XBSA (Bovine serum albumin lmg / ml) 5 ⁇ L were added, and sterilized ultrapure water was added to the mixture to make the volume 50 ⁇ L.
- 10 X buffer solution 330raM Tris-Acetate pH 7.9, 660 mM K0Ac, lOOmM MgOAc 2 , 5 mM Dithiothreitol
- 10 XBSA Bovine serum albumin lmg / ml
- ⁇ group (digestion treatment group with H pa II): In the oligonucleotide solution prepared above, 12 U of Hpa II and 10 X buffer solution (330 mM Tris-Acetate pH 7.9 optimal for Hpall and HhaI) Add 5 ⁇ L of 660 mM thigh c, lOOmM MgOAc 2 , 5 mM Dithiothreitol) and 5 L of 10 XBSA (Bovine serum albumin lmg / ml), and add sterile ultrapure water to the mixture to reduce the volume. 50 L.
- 10 XBSA Bovine serum albumin lmg / ml
- Group C Additional oligonucleotide for masking + digestion with Hpa II: In the oligonucleotide solution prepared above, 12 U of Hp all and 10 X buffer (330 mM) optimal for Hp all and H ha I Tris-Acetate pH 7.9, 660 mM K0Ac, lOOmM MgOAc 2 , 5 mM Dithiothreitol (5), 10 XBSA (Bovine serum albumin lmg / ml) 5 ⁇ L, and masking oligo consisting of the base sequence shown in SEQ ID NO: 19 5 pmo 1 of nucleotide MA was added, and sterilized ultrapure water was further added to the mixture to adjust the volume to 50 ⁇ L. '
- Bio_GPR7-2176R 5,-GCACGACGAGTGTGACGATC -3 '(SEQ ID NO: 20) 5 terminal Piotin for each 50 L of each digested solution of the obtained methylated oligonucleotide or unmethylated oligonucleotide 1 / L of labeled oligonucleotide solution was added and heated at 95 ° C for 5 minutes. After that, it was quickly cooled to 50 ° C and kept at that temperature for 5 minutes. Next, this was kept at 37 ° C. for 5 minutes and then returned to room temperature. Next, the mixture prepared as described above was added to a PCR tube coated with streptavidin, and this was further incubated at 37 ° C for 5 minutes.
- methylation in the target DNA region (GPR 7-20 79-2 1 76, SEQ ID NO: 23, methylated cytosine is also represented by C) is performed. Amplified DNA. > Oligonucleotide primers designed for PCR>
- PR1 5'-GCACGACGAGTGTGACGATC-3 '(SEQ ID NO: 22) 2009/056782
- GPR7-2079-2176 5,-GTTGGCCACTGCGGAGTCGCC GGGATCGTCACACTCGTCGTGC-3 (SEQ ID NO: 23)
- each of the solutions prepared to be 3 ⁇ of the primer consisting of the nucleotide sequence shown in SEQ ID NO: 21 and the primer consisting of the nucleotide sequence shown in SEQ ID NO: 22 on the vertical DNA was used. Shito, and the each 2 mM dNTPs 5 J uL, buffer (lOOmM Tris-HCl pH 8.3, 500mM KC1, 15mM MgCl 2, 0.01% Gelatin) and 5, heat resistance DNA polymerase (AmpliTaq Gold) 511 teeth 0 Then, 10 L of a 5N betaine aqueous solution was mixed, and sterilized ultrapure water was added thereto to make the liquid volume 50 W L. The reaction solution was incubated at 95 ° C for 10 minutes, and then incubated at 95 ° C for 30 seconds, followed by 59 ° C for 30 seconds and 72 ° C for 45 seconds for one cycle. PCR was performed under the same conditions.
- Oligonucleotide of target DNA region (GPR7-2079-2176, methylated cytosine is also represented by C)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/934,428 US20110086356A1 (en) | 2008-03-25 | 2009-03-25 | Method for measuring dna methylation |
CN2009801182625A CN102037139A (zh) | 2008-03-25 | 2009-03-25 | Dna甲基化测定方法 |
EP09724943A EP2272974A4 (en) | 2008-03-25 | 2009-03-25 | DETERMINATION METHOD FOR DNA METHYLATION |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008-077966 | 2008-03-25 | ||
JP2008077966A JP5206059B2 (ja) | 2008-03-25 | 2008-03-25 | メチル化されたdnaの含量を測定する方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009119890A1 true WO2009119890A1 (ja) | 2009-10-01 |
Family
ID=41114070
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2009/056782 WO2009119890A1 (ja) | 2008-03-25 | 2009-03-25 | Dnaメチル化測定方法 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20110086356A1 (ja) |
EP (1) | EP2272974A4 (ja) |
JP (1) | JP5206059B2 (ja) |
KR (1) | KR20100130222A (ja) |
CN (1) | CN102037139A (ja) |
WO (1) | WO2009119890A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103160937B (zh) * | 2011-12-15 | 2015-02-18 | 深圳华大基因科技服务有限公司 | 对高等植物复杂基因组基因进行富集建库和snp分析的方法 |
CN104611410A (zh) * | 2013-11-04 | 2015-05-13 | 北京贝瑞和康生物技术有限公司 | 一种无创癌症检测方法及其试剂盒 |
EP3508588A4 (en) * | 2016-09-02 | 2020-05-27 | Fujifilm Wako Pure Chemical Corporation | METHOD FOR AMPLIFYING METHYLATED DNA, METHOD FOR DETERMINING DNA METHYLATION, AND METHOD FOR DETERMINING THE APPEARANCE OF CANCER |
CN109234388B (zh) * | 2017-07-04 | 2021-09-14 | 深圳华大生命科学研究院 | 用于dna高甲基化区域富集的试剂、富集方法及应用 |
CN110468179B (zh) * | 2018-05-10 | 2021-03-05 | 北京大学 | 选择性扩增核酸序列的方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1334110A2 (en) * | 2000-08-02 | 2003-08-13 | Applera Corporation | Methods for isolating one strand of a double-stranded nucleic acid |
AU2002246612B2 (en) * | 2000-10-24 | 2007-11-01 | The Board Of Trustees Of The Leland Stanford Junior University | Direct multiplex characterization of genomic DNA |
JP2006500901A (ja) * | 2001-09-26 | 2006-01-12 | エピジェンクス ファーマスーティカルズ、 インコーポレイテッド | Dnaメチル化変化のアッセイ |
US20030148284A1 (en) * | 2001-12-17 | 2003-08-07 | Vision Todd J. | Solid phase detection of nucleic acid molecules |
WO2007081791A2 (en) * | 2006-01-04 | 2007-07-19 | The Johns Hopkins University | Compare-ms:method rapid, sensitive and accurate detection of dna methylation |
JP4940939B2 (ja) * | 2006-12-25 | 2012-05-30 | 住友化学株式会社 | Dnaメチル化測定方法 |
JP4940940B2 (ja) * | 2006-12-25 | 2012-05-30 | 住友化学株式会社 | Dnaメチル化測定方法 |
JP5151167B2 (ja) * | 2007-01-31 | 2013-02-27 | 住友化学株式会社 | Dnaメチル化測定方法 |
-
2008
- 2008-03-25 JP JP2008077966A patent/JP5206059B2/ja not_active Expired - Fee Related
-
2009
- 2009-03-25 CN CN2009801182625A patent/CN102037139A/zh active Pending
- 2009-03-25 EP EP09724943A patent/EP2272974A4/en not_active Withdrawn
- 2009-03-25 WO PCT/JP2009/056782 patent/WO2009119890A1/ja active Application Filing
- 2009-03-25 KR KR1020107023673A patent/KR20100130222A/ko not_active Application Discontinuation
- 2009-03-25 US US12/934,428 patent/US20110086356A1/en not_active Abandoned
Non-Patent Citations (12)
Title |
---|
ALLEN, R. CUTLER ET AL.: "Methylation of HpaII and HhaI sites near the polymorphic CAG repeat in the human androgen-receptor gene correlates with X chromosome inactivation.", AMERICAN JOURNAL OF HUMAN GENETICS, vol. 51, no. 6, 1992, pages 1229 - 1239, XP003027646 * |
BUCKLE, MALCOLM. ET AL.: "Real time measurements of elongation by a reverse transcriptase using surface plasmon resonance.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 93, no. 2, 1996, pages 889 - 894, XP002252240 * |
GRUENBAUM ET AL., NUCLEIC ACID RESEARCH, vol. 9, pages 2509 - 2515 |
GRUENBAUM, YOSEF ET AL.: "Restriction enzyme digestion of hemimethylated DNA.", NUCLEIC ACIDS RESEARCH, vol. 9, no. 11, 1981, pages 2509 - 2515, XP008137058 * |
HEISKANEN, MERVI ET AL.: "A novel method to quantitate methylation of specific genomic regions.", PCR METHODS AND APPLICATIONS, vol. 4, no. 1, 1994, pages 26 - 30, XP000465079 * |
M.A. INISU ET AL.: "PCR Jikken Manual", 1991, HBJ SHUPPAN-KYOKU, pages: 5, XP003013987 * |
NUCLEIC ACIDS RES., vol. 22, no. 15, 11 August 1994 (1994-08-11), pages 2990 - 7 |
NYGREN, ANDERS O. H. ET AL.: "Methylation- specific MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequences.", NUCLEIC ACIDS RESEARCH, vol. 33, no. 14, 2005, pages E128 - 1-9, XP002596755 * |
PROC. NATL. ACAD. SCI. U.S.A., vol. 94, no. 6, 18 March 1997 (1997-03-18), pages 2284 - 9 |
SCHMIDT, PETER M. ET AL.: "Detection of activity of telomerase in tumor cells using fiber optical biosensors.", BIOSENSORS & BIOELECTRONICS, vol. 17, no. 11-12, 2002, pages 1081 - 1087, XP001206070 * |
See also references of EP2272974A4 * |
STERKY, FREDRIK ET AL.: "Direct sequencing of bacterial artificial chromosomes (BACs) and prokaryotic genomes by biotin-capture PCR.", JOURNAL OF BIOTECHNOLOGY, vol. 60, no. 1-2, 1998, pages 119 - 129, XP004115549 * |
Also Published As
Publication number | Publication date |
---|---|
US20110086356A1 (en) | 2011-04-14 |
JP5206059B2 (ja) | 2013-06-12 |
JP2009225759A (ja) | 2009-10-08 |
CN102037139A (zh) | 2011-04-27 |
EP2272974A1 (en) | 2011-01-12 |
KR20100130222A (ko) | 2010-12-10 |
EP2272974A4 (en) | 2011-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2019176867A (ja) | 核酸プローブ及びゲノム断片検出方法 | |
US20010018180A1 (en) | Methods for detecting mutations using primer extension for detecting disease | |
JP6169603B2 (ja) | 単一分子のハイブリダイゼーションおよび操作によるdnaの検出および定量法 | |
JP2005501566A (ja) | 一試料中の異なる個体を起源とするdnaの検出方法 | |
JP2005511030A (ja) | 核酸の増幅方法 | |
JP5266828B2 (ja) | メチル化されたdnaの含量を測定する方法 | |
WO2009119890A1 (ja) | Dnaメチル化測定方法 | |
JP4924014B2 (ja) | Dnaメチル化測定方法 | |
JP5151167B2 (ja) | Dnaメチル化測定方法 | |
CA2687171A1 (en) | Amplification method of methylated or unmethylated nucleic acid | |
JP5303981B2 (ja) | Dnaメチル化測定方法 | |
CN114381498A (zh) | 一种基于协同原位组装G-四链体DNAzyme纳米线的化学发光传感器及其应用 | |
JP5277681B2 (ja) | Dnaメチル化測定方法 | |
JP4940940B2 (ja) | Dnaメチル化測定方法 | |
JP4940939B2 (ja) | Dnaメチル化測定方法 | |
CN114787385A (zh) | 用于检测核酸修饰的方法和系统 | |
WO2005026352A1 (ja) | 癌化度評価方法 | |
JP2013074837A (ja) | 哺乳動物由来の検体の癌化度を評価する方法 | |
WO2005026354A1 (ja) | 癌化度評価方法 | |
WO2005026355A1 (ja) | 癌化度評価方法 | |
WO2001016310A1 (fr) | Procede ultra-sensible de detection de la mutation de genes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980118262.5 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09724943 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 6762/CHENP/2010 Country of ref document: IN Ref document number: 2009724943 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20107023673 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12934428 Country of ref document: US |